Guangshengtang (300436.SZ) reported 2023 annual results, with a net loss of 349 million yuan, an increase in year-on-year losses

Guangshengtang (300436.SZ) released its 2023 annual report. The company achieved operating income of 4.2 during the reporting period...

Zhitong FinanceApr 19 11:34 ET

More Unpleasant Surprises Could Be In Store For Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Shares After Tumbling 28%

To the annoyance of some shareholders, Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) shares are down a considerable 28% in the last month, which continues a horrid run for the company. For

Simply Wall StApr 16 18:14 ET

Guangshengtang (300436.SZ): Obtaining a patent certificate or authorization notice for a new drug under development

Gelonghui, April 3 | Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd. (“Guangsheng Zhonglin”), an innovative pharmaceutical holding subsidiary of Fujian Guangshengtang Pharmaceutical Co., Ltd., has actively carried out patent applications on a global scale to provide intellectual property protection for innovative drug research and development since starting innovative drug research and development. Recently, Guangsheng Zhonglin obtained the following patent certificates or authorization notices for new drugs under development. The compounds and morphology of the company's hepatitis B core protein inhibitor GST-HG141 (generic name: nericavir) have applied for international patents through the PCT channel, and have been exhausted up to now

Gelonghui FinanceApr 3 06:03 ET

Guangshengtang (300436.SZ): The total amount involved in the proposed termination of some technical service contracts is RMB 25.613 million

Gelonghui, March 31 | Guangshengtang (300436.SZ) announced that the company and Ruitailai signed a “technical service contract” for 10 drugs in March 2022. In addition to ritonavir tablets, clopidogrel bisulfate, aspirin tablets, and aspirin enteric tablets, this related transaction plans to prematurely terminate the “technical service contracts” for the remaining 7 drugs signed above and sign a “termination agreement”. The total amount involved in the termination of the related transaction agreement was 25.613 million yuan.

Gelonghui FinanceMar 31 04:43 ET

Guangshengtang (300436.SZ) subsidiaries obtained patent certificates or authorization notices for various innovative drugs

Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative pharmaceutical holding subsidiary...

Zhitong FinanceFeb 6 07:25 ET

Fujian Cosunter Pharmaceutical Co., Ltd.'s (SZSE:300436) Popularity With Investors Under Threat As Stock Sinks 25%

The Fujian Cosunter Pharmaceutical Co., Ltd. (SZSE:300436) share price has fared very poorly over the last month, falling by a substantial 25%. For any long-term shareholders, the last month ends a

Simply Wall StFeb 1 18:26 ET